Showing results (251-260 of 378) with videos related to

Sort By:
Pageof 38
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 18, 2003
Primary treatment of multiple myeloma with thalidomide, vincristine, liposomal doxorubicin and dexamethasone (T-VAD doxil): a phase II multicenter studyK Zervas, M A Dimopoulos, E Hatzicharissi, et al.
Radiology|September 1, 1993
Waldenström macroglobulinemia: MR imaging of the spine and CT of the abdomen and pelvisL A Moulopoulos, M A Dimopoulos, D G Varma, et al.
American Journal of Clinical Oncology|June 17, 2000
Successful conservative treatment of neutropenic enterocolitis complicating taxane-based chemotherapy: a report of five casesC Kouroussis, G Samonis, N Androulakis, et al.
Blood Cancer Journal|June 6, 2015
Osteoprotegerin is a significant prognostic factor for overall survival in patients with primary systemic amyloidosis independent of the Mayo stagingE Kastritis, M Gavriatopoulou, M A Dimopoulos, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 3, 2004
Randomised phase III study of intravenous vinorelbine plus hormone therapy versus hormone therapy alone in hormone-refractory prostate cancerR P Abratt, D Brune, M-A Dimopoulos, et al.
Gynecologic Oncology|October 13, 2006
The impact of age in the outcome of patients with advanced or recurrent cervical cancer after platinum-based chemotherapyE Kastritis, A Bamias, G Bozas, et al.
Leukemia|August 5, 2005
The combination of intermediate doses of thalidomide with dexamethasone is an effective treatment for patients with refractory/relapsed multiple myeloma and normalizes abnormal bone remodeling, through the reduction of sRANKL/osteoprotegerin ratioE Terpos, D Mihou, R Szydlo, et al.
Oncology|August 26, 1999
Outpatient treatment of neutropenic fever with oral antibiotics and granulocyte colony-stimulating factorC Papadimitris, M A Dimopoulos, E Kostis, et al.
Urology|January 26, 2005
Combination of docetaxel, estramustine phosphate, and zoledronic acid in androgen-independent metastatic prostate cancer: efficacy, safety, and clinical benefit assessmentE Efstathiou, G Bozas, A Kostakopoulos, et al.
Gynecologic Oncology|July 19, 2011
Prognostic factors for early-stage epithelial ovarian cancer, treated with adjuvant carboplatin/paclitaxel chemotherapy: a single institution experienceA Bamias, A Karadimou, N Soupos, et al.
Pageof 38